TG Therapeutics announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating Briumvi in patients with relapsing forms of multiple sclerosis, or RMS, at the Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, annual forum, being held in West Palm Beach, Florida. Michael Weiss, CEO and chairman of TG Therapeutics stated, “We were pleased to present updated data from the ENHANCE trail evaluating patients switching from a current CD20 to BRIUMVI. It was encouraging to see that patients who switched to one-hour BRIUMVI experienced a manageable safety and tolerability profile. We look forward to continuing to present updated data from this trial throughout the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- TG Therapeutics price target raised to $13 from $12 at Goldman Sachs
- Unusually active option classes on open February 28th
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
- TG Therapeutics reports Q4 EPS (9c), consensus (10c)
